Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1293-1301

  Madden, Timothy ^a   Tran, Hai T ^a   Beck, Debrah ^a   Huie, Reeves ^a   Newman, Robert A ^a   Pusztai, Lajos ^a   Wright, John J ^b   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASTATIN 10; DOLASTATIN 15;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; DRUG DISTRIBUTION; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MOLLUSC; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH; VOMITING;

ADULT; AGED; ANEMIA; ANIMALS; ANOREXIA; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOLLUSCA; NAUSEA; NEOPLASMS; OLIGOPEPTIDES; TREATMENT OUTCOME; VOMITING;

EID: 0034005620     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pettit, G. R., Kamano, Y., Herald, C. L., Fuji, Y., Kizu, H., Boyd, M. R., Boettner, F. E., Doubek, D. L., Schmidt, J. M., Chapius, J-C., and Michiel, C. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc., 109: 6883-6885, 1987.
2. Pettit, G. R., Singh, S. B., Hogan, F., Lloyd-Williams, P., Herald, D. L., Burkett, D. D., and Clewlow, P. J. The absolute configuration and synthesis of natural (-)dolastatin 10. J. Am. Chem. Soc., 111: 5463-5465, 1989.
3. Bai, R., Pettit, G. R., and Hamel, E. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem. Pharmacol., 40: 1859-1864, 1990.
4. Schmidt, J. M., and Pettit, G. R. Presence of oncornavirus-like particles in the P388 murine leukemic cell line. Experientia (Basel), 34: 659-660, 1978.
5. Steube, K. G., Grunicke, D., Pietsch, T., Gignac, G. R., Pettit, G. R., and Drexler, H. G. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells. Leukemia (Baltimore), 6: 1048-1053, 1992.
6. Hu, Z-B., Gignac, S. M., Quentmeier, H., Pettit, G. R., and Drexler, H. G. Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leuk. Res., 17: 333-339, 1993.
7. Jacobsen, S. E., Ruscetti, F. W., Longo, D. L., and Keller, J. R. Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells. J. Natl. Cancer Inst., 83: 1672-1677, 1991.
8. Beckwith, M., Urba, W. J., and Longo, D. L. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J. Natl. Cancer Inst., 85: 483-488, 1993.
9. Aherne, G. W., Hardcastle, A., Valenti, M., Bryant, A., Rogers, P., Pettit, G. R., Srirangam, J. K., and Kelland, L. R. Antitumor evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother. Pharmacol., 38: 225-232, 1996.
10. Bai, R., Pettit, G. R., and Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol., 39: 1941-1949, 1990.
11. Maki, A., Diwakaran, H., Redman, B., al-Asfar, S., Pettit, G. R., Mohammad, R. M., and al-Katib, A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs, 6: 392-397, 1995.
12. Newman, R. A., Fuentes, A., Covey, J. M., and Benvenuto, J. A. Preclinical pharmacology of the natural marine product dolastin 10 (NSC 376128). Drug Metab. Dispos., 22: 428-432, 1994.
13. May, R. D., Murphy, M. J., Jr., Erickson-Miller, C. L., Tomaszewski, J. E., Osborn, B. L., and Page, J. G. Myelotoxicity evaluation of dolastatin 10 (NSC-376128) and swainsonine (NSC-614553) using murine, canine, and human in vitro CFU-GM assays. Proc. Am. Assoc. Cancer Res., 35: 402, 1994.
14. Ajani, J. A., Abbruzzese, J. L., Goudeau, P., Faintuch, J., Yeomans, A., Boman, B., and Levin, B. Ifosfamide and mesna: marginally active in patients with cancer of the pancreas. J. Clin. Oncol., 6: 1703-1707, 1988.
15. Garteiz, D. A., Madden, T., Huie, W. R., McManus, K. T., Abbruzzese, J. L., Chen, W., and Newman, R. A. Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a Phase I clinical trial. Cancer Chemother. Pharmacol., 41: 307-316, 1998.
16. Pitot, H. C., McElroy, E. A., Reid, J. M., Windebank, A. J., Sloan, J. A., Erlichman, C., Bagniewski, P. G., Walker, D. L., Rubin, J., Goldberg, R. M., Adjei, A. A., and Ames, M. M. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res., 5: 525-531, 1999.
17. Clinical Brochure: Dolastatin 10. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1996.